Pushing the forefront of
therapeutic antibody discovery

OmniAb® provides our pharmaceutical industry partners access to the most diverse antibody repertoires and cutting-edge screening technologies to enable discovery of next-generation therapeutics.

Discover the advantage of choosing OmniAb for antibody discovery

OmniAb partners enjoy full access to the most comprehensive and cutting-edge suite of clinically proven antibody discovery technologies available.

Learn about how OmniAb
will best help your program.

Discover our transgenic
animal platforms.

Introduction to
a unique innovation in transgenic animal platforms

Because chickens are evolutionarily more distant than rodents are to humans, they produce stronger and more diverse antibody responses to many target antigens, especially those that are conserved among mammals. This makes chickens ideal immunization hosts for therapeutic antibody discovery. 

Learn About OmniChicken

What's New
at OmniAb

Read the latest news and press
releases about OmniAb technology.
Read News & Press Releases

Publications & Presentations

Search and browse recent presentations and peer-reviewed publications about OmniAb technology

View Publications

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics.

OmniClic: Transgenic Chickens Producing Human Antibodies for Bispecifics.

Become an OmniAb partner

See how more than 75 biopharmaceutical companies and research institutions worldwide are using OmniAb technology and capabilities to advance clinical drug development.

Partner With Us

Get in Touch

Learn about our antibody discovery services
and find out which could work best for you.

Contact Us